INVO Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted EBITDA

Core Insights - INVO Fertility, Inc. reported record revenue of $6.5 million for 2024, a 116% increase compared to 2023, driven by the performance of its fertility clinics across the U.S. [4] - The company is refocusing on its core fertility operations following the decision to divest a majority stake in NAYA TX, aiming to capitalize on favorable market trends and increasing public demand for fertility care [4][5] - The U.S. fertility services market is expected to grow due to rising infertility rates and increasing acceptance of assisted reproductive technologies (ART) [7] Q4 2024 Financial Highlights - Revenue for Q4 2024 was $1,685,966, a 22% increase from $1,381,754 in Q4 2023 [6] - Consolidated clinic revenue from the INVO Center in Atlanta and the fertility clinic in Madison increased by 24% to $1,687,300 [6] - Adjusted EBITDA for Q4 2024 was $(450,908), an improvement from $(1.0) million in the prior year [6][14] 2024 Financial Highlights - Total revenue for 2024 reached $6,532,000, up 116% from $3,020,575 in 2023 [6] - Consolidated clinic revenue increased by 125% to $6,450,431 compared to $2,862,574 in 2023 [6] - Net loss for 2024 was $(9.1) million, compared to $(8.0) million in 2023, attributed to the addition of NAYA Therapeutics and merger costs [6] Management Commentary - The CEO highlighted the streamlined operating structure aimed at achieving positive cash flow and the successful expansion into new markets [4] - The company is actively pursuing expansion opportunities in response to declining U.S. fertility rates and rising demand for fertility solutions [4] Market Context - The global fertility services market is projected to grow, driven by rising infertility rates and delayed parenthood [7] - The Centers for Disease Control and Prevention reported a 50% increase in ART-conceived births from 2012 to 2021, with ART now accounting for 2.3% of all births in the U.S. [7]